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Measurements and Main Results:
Propensity score-adjusted Cox proportional hazards regression models quantified the effect of linezolid compared with vancomycin on time to 30-day mortality (primary outcome), therapy change, hospital discharge, discharge from intensive care, intubation, 30-day readmission, and 30-day MRSA reinfection. In addition, a composite outcome of clinical success was defined as discharge from the hospital or intensive care unit by day 14 after treatment initiation, in the absence of death, therapy change, or intubation by day 14. success, but no significant differences in mortality. 20 Limitations of these studies, specifically their methodological and statistical approaches, have been noted in multiple commentaries. [21] [22] [23] [24] [25] [26] [27] [28] These randomized trials provide important comparative efficacy data; however, they may not reflect the effectiveness of these agents in real-world clinical practice. MRSA pneumonia is a complex disease with significant morbidity and mortality; therefore, evaluating real-world effectiveness in treating this disease is essential. Thus, we sought to quantify the effectiveness of linezolid compared with vancomycin on clinical outcomes for the treatment of MRSA pneumonia in a national Veterans Affairs (VA) cohort.
Methods
The study design and methods were defined a priori in the study protocol, which was reviewed and approved by the Institutional Review Board and Research and Development Committee of the Providence Veterans Affairs Medical Center (Providence, RI).
Data Sources
The Veterans Health Administration has used an electronic medical record system since 1999.
Our study included national standardized databases capturing the following data relevant to 
Statistical Analysis
Between-group differences were assessed using χ 2 or Fisher exact tests for categorical variables and the t-test or Wilcoxon rank sum test for continuous variables as appropriate.
Propensity scores were derived from unconditional logistic regression models. Time-to-event analyses were conducted with Cox proportional hazards regression models. Adjustment was achieved by controlling for propensity score quintiles. The propensity adjusted-Cox proportional hazards regression models were used to quantify the effect of linezolid compared with vancomycin treatment for MRSA pneumonia on the primary and secondary outcomes. A hazard ratio (HR) greater than 1 indicates a higher probability of the event occurring in the linezolid group compared with the reference vancomycin group. In terms of our study outcomes, HRs greater than 1 would represent a higher mortality rate, decreased length of stay (LOS), or higher readmission rate among patients treated with linezolid. All analyses were performed by using SAS statistical software, version 9.1.3 (SAS Institute Inc., Cary, NC).
Results
We identified 5271 patients who met our inclusion criteria, of whom 328 (6.2%) were treated with linezolid and 4943 (93.8%) with vancomycin. The mean patient age was 69 years in both treatment groups (Table 1) . The majority of patients in both groups were white men. Several statistically significant differences in frequency of comorbidities, including renal disease, cancer, and dialysis, were observed between treatment groups. Geographic region of facility and infections in the year prior to admission were characteristics that varied significantly between the linezolid and vancomycin groups ( Table 2) . Although a number of baseline variables differed significantly between the treatment groups, balance was achieved within propensity score quintiles. The propensity score controlled for a number of patient demographics and comorbidities present during the MRSA pneumonia admission, as well as medical history in the year prior to the MRSA pneumonia admission. Several treatment-related characteristics were also controlled for, including time to treatment initiation, year of treatment initiation, hospital unit at treatment initiation, and treating specialty at initiation.
In the overall cohort, the 30-day mortality rate was 20.8% ( 
Discussion
We assessed the real-world effectiveness of linezolid compared with vancomycin in the treatment of MRSA pneumonia in a large cohort of patients admitted to VA facilities nationally.
No significant differences were observed in the primary outcome measure, time to 30-day mortality. These results regarding mortality are similar to findings from a pneumonia subset analysis in a large national cohort study of veterans with MRSA infections. 30 of an association between linezolid and clinical success. In addition to traditional outcome measures, such as mortality, length of stay, and pharmacoeconomics, it is useful to develop outcome measures that are clinically or microbiologically based to assess differences between groups and to assist in clinical decision making. As the prevalence of retrospective clinical studies increase, it is likely that these measures will evolve and be validated over time. 31 We did not observe an association between linezolid treatment and a higher discharge rate for MRSA pneumonia, and thus mean LOS was comparable between treatment groups (linezolid 19.7 days, vancomycin 20.3 days). This finding differs from an earlier national MRSA cohort study, in which linezolid treatment was associated with a shorter LOS. 30 In general, evidence from randomized studies demonstrates a shorter LOS with linezolid treatment. 35, 36 However, these studies included patients with other types of infections, such as complicated skin and soft tissue infections. MRSA pneumonia is a complicated infection with lengthy recommended treatment durations of up to 21 days, depending on the extent of the infection, 37 so it may have been less likely that we would observe differences in LOS and discharge rates in our study than in studies of other infection types.
In our retrospective cohort study, linezolid treatment was associated with a lower rate of therapy change compared with vancomycin treatment in the adjusted overall analysis. Limited data have been published on differences in therapy change with different agents. However, in randomized trials, rates of discontinuation of linezolid or vancomycin were comparable to our findings. 15, 16, 19 It is possible that patients receiving intravenous vancomycin may have been switched to a different antibiotic with an oral option as they were being prepared for discharge.
Comparable rates of time to ICU discharge, intubation, 30-day MRSA reinfection, and 30-day readmission were found between treatment groups in our study. In contrast, a prospective, open-label trial found a nonsignificant trend favoring decreased length of ICU stay with linezolid treatment; however, this trial limited inclusion to patients with MRSA VAP. 38 In retrospective studies, comparable rates of intubation and readmission rates have been found with linezolid compared with vancomycin treatment. 30, 39 Few studies report readmission and reinfection rates due to short follow-up periods.
Our study has several limitations. The retrospective design is associated with a number of limitations, including that ICD-9 coding practices may vary among institutions and affect the accuracy of our findings. In addition, there is discordance with ICD-9 coding and cultureconfirmed MRSA pneumonia infection, 40 thereby leading to a potential misclassification. It is likely our study did not capture all MRSA pneumonia infections due to missing codes for MRSA.
Because of the complexity of obtaining microbiologic data for this study, validation of ICD-9 codes of MRSA pneumonia was performed in a 10% patient sample. In addition, we had no control over culture collection. Of the patients randomly selected for validation, 29% were nonevaluable because no sputum samples were taken. This indicates treatment initiation for suspected MRSA pneumonia, based on clinical signs and symptoms, without ever collecting a sputum culture, which is why we also included a clinical subgroup in our analyses. In the clinical subgroup, results of the chest radiographs were not available in the databases used.
However, patients in the clinical subgroup had to meet all inclusion criteria for the overall cohort in addition to having a chest radiograph between admission and initiation of treatment or one of the other clinical symptoms (elevated body temperature or elevated white blood cell count).
Our study is further limited in that we did not evaluate success in all patients since we excluded those not meeting the definition of success or nonsuccess by day 14 after treatment initiation (linezolid 29.6%, vancomycin 29.2%). It is not known whether vancomycin dosing was optimized among patients included in this study because trough levels were not available for evaluation. Although balance was achieved within propensity score quintiles, there is the potential for residual confounding by unobserved covariates. Finally, the generalizability of our study may be limited to the VA population.
Conclusion
Our retrospective national cohort study demonstrated similar survival, LOS, readmission, and reinfection rates for patients with MRSA pneumonia treated with linezolid or vancomycin.
Linezolid treatment was associated with a significantly higher rate of the composite outcome of clinical success than vancomycin. These real-world clinical data support the results of previous studies and further the understanding of MRSA pneumonia treatment. The propensity score for the overall cohort was derived from an unconditional logistic regression model controlling for race, admission source, region of facility, hospital unit at treatment initiation, treating specialty, chronic renal disease, diabetes mellitus, cancer, metastatic cancer, myocardial infarction, cardiac arrhythmia, obesity, depression, bacteremia, endocarditis, gram-negative infection, Escherichia coli infection, Streptococcus infection, complication of implant or graft, complication of surgery or medical care, amputation procedure, dialysis, intravenous line, urinary catheter, number of inpatient procedures, time to therapy initiation, year, MRSA pneumonia diagnosis code, inpatient admission in the previous 30 days, procedure in the previous 180 days, previous metastatic cancer, previous coronary heart disease, previous congestive heart failure, previous human immunodeficiency virus infection, previous peripheral vascular disease, previous plegia, previous rheumatoid arthritis or connective tissue disease, previous peptic ulcer, previous weight loss, previous depression, previous drug abuse, previous S. aureus infection, previous pneumonia, previous bacteremia, previous surgical site infection, previous skin abscess, previous chronic ulcer, previous infective arthritis, previous vancomycin-resistant Enterococcus infection, previous E. coli infection, and previous intravenous line. 
